Clinical Trial Detail

NCT ID NCT03289962
Title A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Genentech, Inc.
Indications

lung non-small cell carcinoma

cervical cancer

colorectal cancer

hepatocellular carcinoma

triple-receptor negative breast cancer

transitional cell carcinoma

skin squamous cell carcinoma

head and neck squamous cell carcinoma

melanoma

anus cancer

Advanced Solid Tumor

Merkel cell carcinoma

renal cell carcinoma

Therapies

RO7198457

Atezolizumab + RO7198457

Age Groups: adult senior

Additional content available in CKB BOOST